戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  menopausal symptoms, such as hot flashes or vaginal dryness.
2 en about possible remedies, particularly for vaginal dryness.
3               Hot flashes, night sweats, and vaginal dryness.
4 luating the association between migraine and vaginal dryness and between back pain and VMS.
5                 Providing advice on treating vaginal dryness and brief sexual counseling can often al
6                                              Vaginal dryness and dyspareunia are significant estrogen
7 e placebo appear to substantially ameliorate vaginal dryness and dyspareunia in breast cancer survivo
8 presentation, most patients complained about vaginal dryness and dyspareunia with impairment in sexua
9 ts seem to moderately decrease occurrence of vaginal dryness and dyspareunia.
10 en production in postmenopausal women causes vaginal dryness and irritation.
11 or little desire, 80% reported problems with vaginal dryness, and 62% reported pain or discomfort dur
12                           Ongoing treatment, vaginal dryness, and feeling unprepared for the impact o
13 rolling for sexual problems at prediagnosis, vaginal dryness, and lower perceived sexual attractivene
14 d menopausal symptoms including hot flashes, vaginal dryness, and sexual dysfunction.
15 enopause, but only vasomotor dysfunction and vaginal dryness are consistently associated with this ti
16 inal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleep
17 ductions in the frequency of hot flashes and vaginal dryness but no significant reduction in night sw
18 rogesterone acetate (DMPA) likewise promotes vaginal dryness by suppressing ovulation and reducing es
19            During the first 4 weeks, average vaginal dryness decreased by 62% and 64% in the placebo
20 PA injection or ovariectomization models the vaginal dryness detected in women with reduced levels of
21 dicted an increased frequency of VMS but not vaginal dryness during menopausal transition.
22 ge I to III BC taking AIs with self-reported vaginal dryness, dyspareunia, or decreased libido were r
23 ctors of sexual health, several are mutable (vaginal dryness, emotional well-being, body image, the q
24 atients on exemestane plus OFS reported more vaginal dryness, greater loss of sexual interest, and di
25       Hispanic women reported urine leakage, vaginal dryness, heart pounding, and forgetfulness more
26      The distribution of women not reporting vaginal dryness in the past month improved significantly
27                                       Though vaginal dryness in women is typically identified by self
28 as associated with experiencing dyspareunia, vaginal dryness, low libido, and not experiencing orgasm
29 0; 95% confidence interval [CI], 1.63-2.21), vaginal dryness (LR+ range, 1.48-3.79), high follicle-st
30 erican women reported vasomotor symptoms and vaginal dryness more (odds ratios = 1.17-1.63) but urine
31  negative reactions during sex (P = .02) and vaginal dryness or tightness (P = .046).
32 reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P
33 ual dysfunction, including decreased libido, vaginal dryness, pain with intercourse, decreased genita
34  cold sweats and vaginal discharge, yet more vaginal dryness, painful intercourse, and loss of sexual
35 , and the common significant predictors were vaginal dryness, past chemotherapy use, and having a new
36 ence of changes, -0.79 [-1.35 to -0.23]) and vaginal dryness score (pooled mean difference of changes
37 changes, -1.31 [95% CI, -2.02 to -0.61]) and vaginal dryness score (pooled mean difference of changes
38 st and sleep disturbance at 6 months, and by vaginal dryness up to 60 months.